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ABSTRACT
17-Acetylaphidicolin was 10-fold weaker and two derivatives lacking
hydroxyl groups at the 16 and 17 positions were 100-fold weaker than
aphidicolin as inhibitors of DNA polymerase a from HeLa and Chinese hamster
ovary cells. 17,18-Diacetyl, 3,17,18-triacetyl and 3-epi derivatives of
aphidicolin were inactive. Active compounds were, like aphidicolin,
competitive with dCTP and did not inhibit aphidicolin-resistant DNA
polymerases.
INTRODUCTION
Aphidicolin [1] is a potent inhibitor of eukaryotic DNA polymerase a.
The enzyme from sea urchin embryos (1), rat liver (2) and cultured cells,
e.g. HeLa (3,4) and KB (5), is highly sensitive to the drug (Ki ca. 0.5
pM). The recently described DNA polymerase 6, derived both from primary
mammalian tissues (6-8) and from CV-1 cells (9), has also been reported to be
equally sensitive to 1. Although aphidicolin is selective with respect to
the other eukaryotic and bacterial DNA polymerases, it does inhibit the DNA
polymerases encoded by Herpes simplex type 1 and vaccinia viruses (10) and
the a-like DNA polymerases of yeast (11) and plant cells (12). The
mechanism of action of 1 on purified DNA polymerase a is unknown, but its
effect has most often been reported to be competitive with dCTP and
noncompetitive with the other dNTP substrates (1,5,10,13), a result also
observed with sensitive viral (10) and plant (12) polymerases. We have been
intrigued by the spectrum of polymerases sensitive to aphidicolin, by the
competitive nature of its action, and by the apparent lack of structural
similarity between it and dCTP or any other dNTP. The hydroxyl groups of
aphidicolin [1] are situated at opposite ends of a rigid hydrophobic
cylindrical structure, and superficially resemble pairs of oxygens in a
deoxyribose ring. As a first step in understanding the mechanism of
aphidicolin, we sought to measure the effects of changes in its hydroxyl
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groups on inhibitory activity. Recently, two naturally occurring derivatives
of 1, 17-acetylaphidicolin [2] and 3-deoxyaphidicolin were reported to
inhibit sea urchin DNA polymerase a with potencies similar to that of the
parent compound (14). In contrast, a recent paper claimed that 2, among
other semisynthetic aphidicolin derivatives, did not inhibit DNA polymerase
a from KB cells (15). We wish to report the effects of blocking or removal
of selected hydroxyl groups of aphidicolin on inhibitory activity toward two
DNA polymerase a's. The results demonstrate that neither intact polar end
of 1 is required for expression of inhibitory activity, and that active
derivatives demonstrate the same kinetics of inhibition and have selectivity
similar to that of aphidicolin.
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MATERIALS AND METHODS
Compounds. Aphidicolin [1] was obtained from the Pharmaceuticals Division,
Imperial Chemical Industries Ltd. and from the Natural Products Branch,
National Cancer Institute. Compound 6 was a gift from Imperial Chemical
Industries Ltd., and the other derivatives, 2-5 and 7, were synthesized and
purified as described (16).
Thin layer chromatograRhy (TLC). Purity of all compounds was determined by
TLC on aluminum-backed silica gel plates (Merck) with 10% methanol in
chloroform as eluant. Plates were developed by immersion in a solution of 5%
anisaldehyde and 1 M sulfuric acid in ethanol, followed by heating on a
hotplate. Rf values for the compounds in this system were: 0.33 [1], 0.47
[2], 0.52 [3], 0.73 [4], 0.52 [5], 0.61 [6] and 0.27 [7]. As little as 0.01%
of aphidicolin could be detected visually in the presence of any other
derivative.
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DNA polymerases. DNA polymerase a from HeLa cells (17) and from Chinese
hamster ovary (CHO) cells (18) and DNA polymerase III from L subtilis (19)
were isolated as described. Reverse transcriptase from avian myeloblastosis
virus (AMV RT) was obtained from Life Sciences Inc., St. Petersburg, FL.
Polymerase assays. DNA polymerase assays were done as reported by Khan and
Brown (18). Assays typically measured acid-precipitable radioactivity
incorporated into DNase-activated calf thymus DNA in the absence of the
competitive substrate dCTP ("truncated assay"), and in the presence of 50
pM dGTP, dATP and [3H]TTP (460 cpm/pmol). Control activities
corresponded to the incorporation of 6.57 and 12.0 pmol [3H]TMP into
activated DNA per 50 4l assay tube by the HeLa and CHO enzymes,
respectively. Classical Ki determinations employed variable concentrations
of [3H]dCTP (650 cpm/pmol) and 50 j&M of the remaining dNTPs in the
presence of several concentrations of test compounds. The results were
analyzed as double reciprocal plots, and Ki values were obtained from Dixon
plots as illustrated for compound 5 in the Figure. DNA polymerase III was
assayed according to Clements et al. (19) with activated DNA and 50 pM
dNTPs; control [3H]TMP incorporations in the absence and presence of dCTP
were 10.2 and 30.3 pmol/assay tube, respectively. AMV RT assays were done as
described previously (20) with activated DNA and dNTPs at 50 OM; control
assays corresponded to incorporation of 5.9 and 17.3 pmol [3H]TMP/assay
tube in the absence and presence of dCTP, respectively. Inhibitor stock
solutions were prepared in dimethylsulfoxide and diluted into enzyme assay
mixtures; the solvent (<5Z) had no effect on the polymerase control assays.
RESULTS AND DISCUSSION
Inhibition of DNA polymerase a by aphidicolin derivatives.
Aphidicolin [1] inhibited both HeLa and CHO cell DNA polymerase a with Ki
values below 1 pM, consistent with results obtained previously (3,4). The
results summarized in the Table show that the Ki values obtained in the
truncated, dCTP-deficient assay with both enzymes were identical to those
obtained from classical kinetic experiments with the CHO enzyme, as expected
if inhibitor is competitive with the deficient substrate (2). Among the
synthetic derivatives, 17-acetylaphidicolin [2] inhibited both polymerases,
but with about 10-fold lower potency than 1. Two derivatives lacking the
hydroxyl groups at the 16 and 17 positions, 3,18-dihydroxy-17-noraphidicolan-
16-one [5] and 3,18-dihydroxy-17-noraphidicolane [6], were about 100-fold
less active than 1. Inhibition by the derivatives was still competitive with
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Table. Inhibitory activity of aphidicolin and derivatives
a from HeLa and CHO cells.
K. values (M)1
on DNA polymerase
1K. values (truncated) were determined in assays lacking dCTP and
represent drug concentrations causing half-maximal inhibition of 3enzyme
activity. Ki values (kinetic) were determined in assays using [ H]dCTP
as variable substrate and from Dixon plots of the results. See MATERIALS
AND METHODS for dstails. Inactive compounds gave <10% inhibition at 100
pM concentration. not done
A B
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Figure. Kinetic analysis of inhibition of CHQ3 DNA polymerase a by 5. The
enzyme was assayed with activated DNA and[ H]dCTP as variable substrate
with 50 uM of the other dNTPs (see MATERIALS AND METHODS). Control assays
with labeIled substrate at 2, 4 and 8 pM incorporated 15.1, 23.1 and 33
pmol of [ H]dCMP per assay tube, respectively. Panel A: Lineweaver Burk
plot of enzyme activity in the presence of no drug (.) and 20 (o), 40 (4) and
80 (4) pM 5. 3Panel B: Dixon plot of enzyme activity in the presence of 5
assayed with I H]dCTP at 2 (A), 4 (o) and 8 (e) pM.
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dCTP, as illustrated by the results shown in the Figure for 5. Blocking of
both ends of 1 to produce 17,18-diacetyl [3] and 3,17,18-triacetylaphidicolin
[4] did, however, completely abolish inhibitory activity (see Table). Our
observation of potent inhibition of DNA polymerase a by 2 is consistent
with the report of Haraguchi et al. (14) that this compound inhibited the sea
urchin enzyme with Ki 2.6 jiM, but contradicts that of Hiranuma et al.
(15) in which 2, 5 and other 17-substituted aphidicolin derivatives were
inactive against KB cell DNA polymerase a. We are confident that the
activities reported in the Table for 2, 5 and 6 are indeed due to the
derivatives and not, for example, to residual aphidicolin. TLC analyses (see
MATERIALS AND METHODS) confirmed that the derivatives contained less than
0.01% of aphidicolin or another derivative. A derivative in which the
configuration about C-3 is altered, 3-epiaphidicolin [7], was inactive
against CHO DNA polymerase a at concentrations up to 100 pM (Table).
Recently, 7 was also reported to be inactive against the KB cell enzyme
(15). Although this result indicates a high degree of stereospecificity of
interaction of this part of aphidicolin with DNA polymerase a, the 3p-OH
group does not appear to be essential for activity: for example,
3-deoxyaphidicolin, lacking the relevant hydroxyl group, was a potent
inhibitor (Ki - 1.3 uM) of the sea urchin enzyme (14). In addition, both
3-deoxyaphidicolin and the 3-oxo derivative were reported to have "one-third"
of the activity of 1 against the KB cell DNA polymerase a (15).
Our results for compounds 2, 5 and 6 and the results from the literature
cited above for the 3-deoxy and 3-oxo derivatives of aphidicolin clearly show
that neither intact functional end of 1 is absolutely required for expression
of DNA polymerase a inhibition. Simultaneous blocking of both ends of 1
(compounds 3 and 4) did, however, completely abolish inhibitory activity.
Active derivatives are competitive with dCTP.
We questioned if alterations of 1 might have produced active compounds that
inhibited DNA polymerase a with different kinetics. In assays of HeLa DNA
polymerase a under truncated, dCTP-deficient conditions, addition of 0.5 mM
of both dGTP and dATP caused no decrease in inhibition by 1, 2, 5 or 6 at
concentrations that inhibited the enzyme by 80-90%. However, addition of 0.5
mM dCTP in these assays completely reversed inhibition (results not shown).
Substantially the same results were obtained with the CHO enzyme for 1, 2 and
5 by classical kinetic analysis. As summarized in the Table and illustrated
in the Figure for compound 5, inhibition was competitive with dCTP and
noncompetitive with the other dNTPs (latter results not shown).
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Aphidicolin derivatives do not inhibit aphidicolin-resistant DNA polymerases.
Aphidicolin at 120 pM did not inhibit the E. coli DNA polymerases, nor at
240 pM did it inhibit AMV reverse transcriptase (10). We repeated similar
assays of aphidicolin and several of its derivatives with B. subtilis DNA
polymerase III and AMV RT to determine if structural modification might
reveal sensitivity of enzymes normally resistant to 1. Neither aphidicolin
nor compounds 2, 3 or 5 at 200 pM inhibited the bacterial enzyme or the
reverse transcriptase when assayed with activated DNA under truncated (-dCTP)
or complete mix conditions. Aphidicolin at 200 pM also did not inhibit AMV
RT in reactions employing oligo dT-poly A and [3H]TTP as template and
substrate, in agreement with the results of reference 10 (results not shown).
CONCLUSIONS
The results reported in this paper and those of related papers (14,15)
suggest that 1 binds via both functional (hydroxylated) ends to two sites on
DNA polymerase a, at least one of which is a site that binds dCTP, probably
as a substrate. Either polar end of the molecule can be modified, but not
both, and the resulting compounds can retain strong to moderate ability to
bind and inhibit DNA polymerase a. Modifications of 1 reported in this
paper did not alter the kinetics of inhibition by active compounds, nor did
any of the derivatives inhibit enzymes that are normally resistant to 1.
Acetylation of the 17-OH group at the "upper end" of 1 (see structure)
decreased activity 10-fold, whereas removal of the 17-carbon, leaving 16-oxo
or 16-(H2) groups, decreased activity an additional 10-fold, suggesting the
loss of hydrogen bonding interactions that may stabilize the
aphidicolin:enzyme complex. Specific interactions of this part of
aphidicolin with enzyme are, therefore, probably not crucial to its binding,
and inactivity of compounds bearing 17-substituents more bulky than acetyl
(15) may result from steric repulsion. The "lower end" of 1, in contrast,
cannot tolerate either a bulky substituent (compounds 3 and 4) or a change in
configuration at C-3 (compound 7). Paradoxically, activity is little
affected by oxidation of the 3-OH group, according to published results (15),
or to its complete removal: the latter compound, 3-deoxyaphidicolin, was
reported to be both a potent inhibitor of sea urchin and HeLa DNA polymerase
a and competitive only with dCTP (14). The observations that the
inhibitory activity of compounds modified at the "upper end" was also
competitive with dCTP and that a configurational change at C-3 abolished
5112
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activity would argue that the "lower end" of the molecule is that region that
occupies or overlaps with a dCTP binding site on DNA polymerase a.
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